NSAID Kullanan Her Hastada Gastrik Profilaksi Gerekli mi?

Yıl 2020, Cilt: 15 Sayı: 3, 69 - 75, 16.10.2020

Kadir Gişi Murat İspiroğlu Bülent Kantarçeken

https://doi.org/10.17517/ksutfd.671049

Öz

Non-steroid anti-inflamatuar ilaçları (NSAID) (Aspirin dahil) kullananlarda risk faktörlerine bağlı olarak; %3- 4.5 klinik gastrointestinal (GİS) sistem olayı, 1/70 semptomatik ülser, 1/5 endoskopik ülser, %1.5 (1-4) (major kanama, perforasyon, obstruksiyon vd.) ciddi komplikasyon, 1/150 kanayan ülser, 1/1200 ölüm gelişeceği tahmin edilmektedir. Non-steroid ani-inflamatuar ilaçlar (NSAID) (Aspirin dahil) gastrik ve düodenal ülserle ilişkili anlamlı derecede morbidite ve mortaliteye neden olurlar. Gastrointestinal olay gelişiminde NSAID’ların kendine ait özelliklerine göre risk 20 kata kadar, seçilen doza görede risk 3-7 kata kadar değişebilmektedir. Helicobacter pylori (H. Pylori) ve NSAID peptik ülser oluşumunda bağımsız iki risk faktörüdür. H.pylori eradikasyonu ülser komplikasyonlarını azaltmaktadır. NSAİD kullanan yüksek riskli hastalarda öncelikle misoprostol ( 600mg/gün ve üstü) veya PPI önerilmelidir.Bu derlemede NSAİ ilaç kullanan ve kullanmak zorunda olan hastalarda GİS proflaksisi gerekliliğinin değerlendirilmesi amaçlandı.

Anahtar Kelimeler

Primer proflaksi, , NSAİİ kullanımı, , Proton pompa inhibitörü

Kaynakça

• 1. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001 Feb;120(3):594-606.
• 2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999 Jun 17;340(24):1888-99.
• 3. Henry McQuay, 10th World Congress on Pain ( in; overcoming difficulties in acute pain management in chronic pain sufferers. The Pharmaceutical Journal 2002 vol: 269 pp;332-332)
• 4. Wallace, JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997; 112:1000.).
• 5. Wolfe MM, Lichtenstein DR, Sing G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888-1899.
• 6. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH.Clin Exp Pharmacol Physiol. 1996 May;23(5):432-4.
• 7. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004 Jul;63(7):759-66. Review.
• 8. Elliott et al 1994; Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol. 1994;23(4):171-6.
• 9. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 1996 Jul;6(3):489-504.
• 10. Brown GJ, Yeomans ND. Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf. 1999 Dec;21(6):503-12.
• 11. Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics. 2001;19 Suppl 1:33-47
• 12. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002 Apr;29(4):804-12.
• 13. Singh G, Rosen Ramey D.NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998 May;51:8-16. Review.
• 14. Peura DA, Lanza FL, Gostout CJ, Foutch PG. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol. 1997 Jun;92(6):924-8.
• 15. Okan A, Tankurt E, Aslan B.U, Akpınar H, Sımsek I, Gonen O. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study. Journal of Gastroenterology and Hepatology (2003) 18, 18–25
• 16. D. Dıncer, A. Duman, H. Dıkıcı, C. Arıcı, I . Suleymanlar, F. Isıtan. Nsaıd-Related Upper Gastrointestinal Bleeding: Are Risk Factors Considered During Prophylaxis? Int J Clin Pract, May 2006, 60, 5, 546–548
• 17. Lanza, FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:2037.
• 18. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998 Jul 27;105(1B):31S-38S.
• 19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999 Jun 17;340(24):1888-99.
• 20. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S60-6.
• 21. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-42.
• 22. Wolfe MM. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. Int J Clin Pract Suppl. 2003 Apr;(135):32-7.
• 23. Kaufmann DW, Kelly JP, Wilholm BE, Laszlo A, Sheehan JE, Koff RS et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 1999;94:3189-3196
• 24. De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999 Oct 23;319(7217):1106-9.
• 25. Wessınger S, Kaplan M, Choı L, Williams M, Lau C, Sharp L et.al. Increased Use Of Selective Serotonin Reuptake İnhibitors İn Patients Admitted With Gastrointestinal Haemorrhage: A Multicentre Retrospective Analysis Aliment Pharmacol Ther 2006; 23, 937–944
• 26. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000 Sep;95(9):2218-24.
• 27. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002 Sep;54(3):320-6.
• 28. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183-7.
• 29. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908. Review.
• 30. Garcia R LA, Hernandez DS. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001
• 31. Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists. J Rheumatol. 2006 Apr;33(4):779-84.
• 32. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998 Sep 26;352(9133):1016-21. Erratum in: Lancet 1998 Nov 4;352(9140):1634
• 33. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997 Oct 4;350(9083):975-9.
• 34. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002 Jan 5;359(9300):9-13.
• 35. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001 Mar 29;344(13):967-73.)
• 36. Huang JQ, Srisar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta–analysis. Lancet 2002;359 (9300):14-22.
• 37. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002 Apr;16(4):779-86.
• 38. Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1091-7.
• 39. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001 Feb;120(3):594-606.
• 40. Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol. 2005 Jan;59(1):118-9
• 41. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000 Sep 21;343(12):834-9
• 42. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.Br J Clin Pharmacol. 2002 Sep;54(3):320-6.
• 43. García Rodríguez LA, Jick H.Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.Lancet. 1994 Mar 26;343(8900):769-72.
• 44. Gutthann SP, Garcia LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997;8(1):18-24.
• 45. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993 Jul 26;153(14):1665-70.
• 46. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA.Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.Ann Intern Med. 1991 Feb 15;114(4):257-63.
• 47. Weil J, Langman M J S, Wainwright P, D Lawson, M Rawlins, R Logan et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31
• 48. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43:1905-1915.
• 49. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C ,et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123:1006-1012.
• 50. Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N.Aliment Pharmacol Ther.Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. 2003 Feb;17(3):321-32.
• 51. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications–review and recommendations based on risk assessment Aliment Pharmacol Ther 2004;19:1051-1061.
• 52. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19:197-208.
• 53. Lanas A. Review article: recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs – a gastroenterologist's perspective. Aliment Pharmacol Ther symp ser 2005; 1(1): pp 16–19 (4).
• 54. Tannenbaum H, Bombardıer C, Davıs P, Anthony S. Russell. An Evidence-Based Approach To Prescribing Nonsteroidal Antiinflammatory Drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57
• 55. American Gastroenterological Association; Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.Clin Gastroenterol Hepatol. 2006 Sep;4(9):1082-9.
• 56. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M et al ; Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007 Mar;102(3):507-15.
• 57. Bhatt D L. ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Risk Circulation October 28, 2008. Downloaded from circ.ahajournals.org by on October 16, 2008. (Published online 3 October 2008)